High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia

Benjamin W Teh; William Chui; Sasanka Handunnetti; Constantine Tam; Leon J Worth; Karin A Thursky; Monica A Slavin

doi:10.1080/10428194.2018.1543884

High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia

Leuk Lymphoma. 2019 Jun;60(6):1572-1575. doi: 10.1080/10428194.2018.1543884. Epub 2019 Jan 11.

Authors

Benjamin W Teh^{1

2

3}, William Chui¹, Sasanka Handunnetti⁴, Constantine Tam^{4

5}, Leon J Worth^{1

2

3}, Karin A Thursky^{1

2

3}, Monica A Slavin^{1

2

3}

Affiliations

¹ a Department of Infectious Diseases , Peter MacCallum Cancer Centre , Parkville , Australia.
² b National Centre for Infections in Cancer , Parkville , Australia.
³ c Sir Peter MacCallum Department of Oncology , University of Melbourne , Parkville , Australia.
⁴ d Department of Haematology , Peter MacCallum Cancer Centre , Parkville , Australia.
⁵ e Department of Haematology , St Vincent's Hospital , Fitzroy , Australia.

PMID: 30632838
DOI: 10.1080/10428194.2018.1543884

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Drug Resistance, Neoplasm
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Mycoses / diagnosis*
Mycoses / etiology*
Piperidines
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Recurrence

Substances

Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Adenine